CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
Romanski, Annette, Uherek, Christoph, Bug, Gesine, Seifried, Erhard, Klingemann, Hans, Wels, Winfried S., Ottmann, Oliver G., Tonn, Torsten
Published in Journal of cellular and molecular medicine (01.07.2016)
Published in Journal of cellular and molecular medicine (01.07.2016)
Get full text
Journal Article
Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
Schönfeld, Kurt, Herbener, Peter, Zuber, Chantal, Häder, Thomas, Bernöster, Katrin, Uherek, Christoph, Schüttrumpf, Jörg
Published in Pharmaceutical research (01.06.2018)
Published in Pharmaceutical research (01.06.2018)
Get full text
Journal Article
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
Ikeda, Hiroshi, Hideshima, Teru, Fulciniti, Mariateresa, Lutz, Robert J, Yasui, Hiroshi, Okawa, Yutaka, Kiziltepe, Tanyel, Vallet, Sonia, Pozzi, Samantha, Santo, Loredana, Perrone, Giulia, Tai, Yu-Tzu, Cirstea, Diana, Raje, Noopur S, Uherek, Christoph, Dälken, Benjamin, Aigner, Silke, Osterroth, Frank, Munshi, Nikhil, Richardson, Paul, Anderson, Kenneth C
Published in Clinical cancer research (15.06.2009)
Published in Clinical cancer research (15.06.2009)
Get full text
Journal Article
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells
Müller, Tina, Uherek, Christoph, Maki, Guitta, Chow, Kai Uwe, Schimpf, Annemarie, Klingemann, Hans-Georg, Tonn, Torsten, Wels, Winfried S.
Published in Cancer Immunology, Immunotherapy (01.03.2008)
Published in Cancer Immunology, Immunotherapy (01.03.2008)
Get full text
Journal Article
Retargeting of natural killer–cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction
Uherek, Christoph, Tonn, Torsten, Uherek, Barbara, Becker, Sven, Schnierle, Barbara, Klingemann, Hans-Georg, Wels, Winfried
Published in Blood (15.08.2002)
Published in Blood (15.08.2002)
Get full text
Journal Article
NK cells engineered to express a GD 2 ‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin
Esser, Ruth, Müller, Tina, Stefes, Dörthe, Kloess, Stephan, Seidel, Diana, Gillies, Stephen D., Aperlo‐Iffland, Christel, Huston, James S., Uherek, Christoph, Schönfeld, Kurt, Tonn, Torsten, Huebener, Nicole, Lode, Holger N., Koehl, Ulrike, Wels, Winfried S.
Published in Journal of cellular and molecular medicine (01.03.2012)
Published in Journal of cellular and molecular medicine (01.03.2012)
Get full text
Journal Article
NK cells engineered to express a GD2‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin
Esser, Ruth, Müller, Tina, Stefes, Dörthe, Kloess, Stephan, Seidel, Diana, Gillies, Stephen D., Aperlo‐Iffland, Christel, Huston, James S., Uherek, Christoph, Schönfeld, Kurt, Tonn, Torsten, Huebener, Nicole, Lode, Holger N., Koehl, Ulrike, Wels, Winfried S.
Published in Journal of cellular and molecular medicine (01.03.2012)
Published in Journal of cellular and molecular medicine (01.03.2012)
Get full text
Journal Article
A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway
Helling, Bianca, König, Martin, Dälken, Benjamin, Engling, Andre, Krömer, Wolfgang, Heim, Katharina, Wallmeier, Holger, Haas, Jürgen, Wildemann, Brigitte, Fritz, Brigitte, Jonuleit, Helmut, Kubach, Jan, Dingermann, Theodor, Radeke, Heinfried H, Osterroth, Frank, Uherek, Christoph, Czeloth, Niklas, Schüttrumpf, Jörg
Published in Immunology and cell biology (01.04.2015)
Published in Immunology and cell biology (01.04.2015)
Get full text
Journal Article
CD 19‐ CAR engineered NK ‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
Romanski, Annette, Uherek, Christoph, Bug, Gesine, Seifried, Erhard, Klingemann, Hans, Wels, Winfried S., Ottmann, Oliver G., Tonn, Torsten
Published in Journal of cellular and molecular medicine (01.07.2016)
Published in Journal of cellular and molecular medicine (01.07.2016)
Get full text
Journal Article
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging
Daldrup-Link, Heike E, Meier, Reinhardt, Rudelius, Martina, Piontek, Guido, Piert, Morand, Metz, Stephan, Settles, Marcus, Uherek, Christoph, Wels, Winfried, Schlegel, Jürgen, Rummeny, Ernst J
Published in European radiology (01.01.2005)
Published in European radiology (01.01.2005)
Get full text
Journal Article
Tracking of [18 F]FDG-labeled natural killer cells to HER2/neu-positive tumors
Meier, Reinhard, Piert, Morand, Piontek, Guido, Rudelius, Martina, Oostendorp, Robert A, Senekowitsch-Schmidtke, Reingard, Henning, Tobias D, Wels, Winfried S, Uherek, Christoph, Rummeny, Ernst J, Daldrup-Link, Heike E
Published in Nuclear medicine and biology (01.07.2008)
Published in Nuclear medicine and biology (01.07.2008)
Get full text
Journal Article
BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib
Zuber, Chantal, Daelken, Benjamin, Aigner, Silke, Haeder, Thomas, Ab, Olga, Whiteman, Kathleen, Hideshima, Teru, Lutz, Robert J, Osterroth, Frank, Uherek, Christoph
Published in Blood (19.11.2010)
Published in Blood (19.11.2010)
Get full text
Journal Article
BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Jagannath, Sundar, Chanan-Khan, Asher A., Heffner, Leonard T, Avigan, David, Lutz, Robert J, Uherek, Christoph, Osterroth, Frank, Ruehle, Markus, Haeder, Thomas, Niemann, Gabriele, Wartenberg-Demand, Andrea, Munshi, Nikhil C., Anderson, Kenneth C.
Published in Blood (19.11.2010)
Published in Blood (19.11.2010)
Get full text
Journal Article
BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Jagannath, Sundar, Chanan-Khan, Asher, Heffner, Leonard T., Avigan, David, Zimmerman, Todd M., Lonial, Sagar, Lutz, Robert J., Engling, Andre, Uherek, Christoph, Osterroth, Frank, Ruehle, Markus, Beelitz, Michelle A., Niemann, Gabriele, Wartenberg-Demand, Andrea, Haeder, Thomas, Anderson, Kenneth C., Munshi, Nikhil C.
Published in Blood (18.11.2011)
Published in Blood (18.11.2011)
Get full text
Journal Article
IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOF
DAELKEN BENJAMIN, UHEREK CHRISTOPH, GERMER MATTHIAS, ZENG STEFFEN, AIGNER SILKE, BRUECHER CHRISTOPH, SCHULZ GREGOR, KRAUS ELMAR, OSTERROTH FRANK, HAEDER THOMAS
Year of Publication 11.03.2016
Get full text
Year of Publication 11.03.2016
Patent
Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Chanan-Khan, Asher A., Jagannath, Sundar, Heffner, Leonard T., Avigan, David, Lee, Kelvin P., Lutz, Robert J, Haeder, Thomas, Ruehle, Markus, Uherek, Christoph, Wartenberg-Demand, Andrea Barbara, Munshi, Nikhil, Anderson, Kenneth C.
Published in Blood (20.11.2009)
Published in Blood (20.11.2009)
Get full text
Journal Article